Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Lykkemark

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Trends in Biotechnology|March 31, 2015
Selection strategies for anticancer antibody discovery: searching off the beaten pathDavid Sánchez-Martín, Morten Dræby Sørensen, Simon Lykkemark, et al.
Free Radical Biology & Medicine|October 17, 2015
Identification of an unstable 4-hydroxynoneal modification on the 20S proteasome subunit α7 by recombinant antibody technologyJesper Just, Tobias Jung, Niels Anton Friis, et al.
Microcirculation (New York, N.Y. : 1994)|February 26, 2017
Pericyte modulation by a functional antibody obtained by a novel single-cell selection strategyJesper Just, Simon Lykkemark, Charlotte H Nielsen, et al.
Frontiers in Immunology|August 17, 2019
Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic TrimerbodiesKasper Mikkelsen, Seandean Lykke Harwood, Marta Compte, et al.
Immunologic Research|May 13, 2015
Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sectionsSimon Asbjørn Larsen, Theresa Meldgaard, Agla J Fridriksdottir, et al.
Cancer Genomics & Proteomics|December 29, 2015
Raising an Antibody Specific to Breast Cancer Subpopulations Using Phage Display on Tissue SectionsSimon Asbjørn Larsen, Theresa Meldgaard, Agla Jael Rubner Fridriksdottir, et al.
Communications Biology|March 9, 2021
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinityOle A Mandrup, Sui Ching Ong, Simon Lykkemark, et al.
Oncoimmunology|January 4, 2018
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapySeandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, et al.
Nature Communications|November 17, 2018
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicityMarta Compte, Seandean Lykke Harwood, Ines G Muñoz, et al.
Oncoimmunology|April 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor responseLaura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Trends in Biotechnology|March 31, 2015
Selection strategies for anticancer antibody discovery: searching off the beaten pathDavid Sánchez-Martín, Morten Dræby Sørensen, Simon Lykkemark, et al.
Free Radical Biology & Medicine|October 17, 2015
Identification of an unstable 4-hydroxynoneal modification on the 20S proteasome subunit α7 by recombinant antibody technologyJesper Just, Tobias Jung, Niels Anton Friis, et al.
Microcirculation (New York, N.Y. : 1994)|February 26, 2017
Pericyte modulation by a functional antibody obtained by a novel single-cell selection strategyJesper Just, Simon Lykkemark, Charlotte H Nielsen, et al.
Frontiers in Immunology|August 17, 2019
Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic TrimerbodiesKasper Mikkelsen, Seandean Lykke Harwood, Marta Compte, et al.
Immunologic Research|May 13, 2015
Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sectionsSimon Asbjørn Larsen, Theresa Meldgaard, Agla J Fridriksdottir, et al.
Cancer Genomics & Proteomics|December 29, 2015
Raising an Antibody Specific to Breast Cancer Subpopulations Using Phage Display on Tissue SectionsSimon Asbjørn Larsen, Theresa Meldgaard, Agla Jael Rubner Fridriksdottir, et al.
Communications Biology|March 9, 2021
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinityOle A Mandrup, Sui Ching Ong, Simon Lykkemark, et al.
Oncoimmunology|January 4, 2018
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapySeandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, et al.
Nature Communications|November 17, 2018
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicityMarta Compte, Seandean Lykke Harwood, Ines G Muñoz, et al.
Oncoimmunology|April 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor responseLaura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood, et al.
Pageof 3